Effect of Eplerenone on Maintenance of Sinus Rhythm After Catheter Ablation in Patients With Long-Standing Persistent Atrial Fibrillation

Several studies have demonstrated a relation between the rennin-angiotensin-aldosterone system and atrial fibrillation (AF), but there are no reports on the effect of eplerenone, a selective aldosterone blocker, on the prevention of AF recurrence after radiofrequency catheter ablation (RFCA). The ai...

Full description

Saved in:
Bibliographic Details
Published in:The American journal of cardiology 2013-04, Vol.111 (7), p.1012-1018
Main Authors: Ito, Yoko, MD, Yamasaki, Hiro, MD, Naruse, Yoshihisa, MD, Yoshida, Kentaro, MD, Kaneshiro, Takashi, MD, Murakoshi, Nobuyuki, MD, Igarashi, Miyako, MD, Kuroki, Kenji, MD, Machino, Takeshi, MD, Xu, Dongzhu, MD, Kunugita, Fusanori, MD, Sekiguchi, Yukio, MD, Sato, Akira, MD, Tada, Hiroshi, MD, Aonuma, Kazutaka, MD
Format: Article
Language:English
Subjects:
Atrial Fibrillation - drug therapy
Atrial Fibrillation - surgery
Biomarkers - blood
Cardiac arrhythmia
Cardiovascular
Cardiovascular disease
Catheter Ablation - methods
Catheters
Chi-Square Distribution
Combined Modality Therapy
Drug therapy
Electrocardiography, Ambulatory
Female
Humans
Male
Middle Aged
Mineralocorticoid Receptor Antagonists - therapeutic use
Proportional Hazards Models
Retrospective Studies
Risk Factors
Spironolactone - analogs & derivatives
Spironolactone - therapeutic use
Treatment Outcome
Veins & arteries
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Several studies have demonstrated a relation between the rennin-angiotensin-aldosterone system and atrial fibrillation (AF), but there are no reports on the effect of eplerenone, a selective aldosterone blocker, on the prevention of AF recurrence after radiofrequency catheter ablation (RFCA). The aim of this study was to evaluate the effects of eplerenone on clinical outcomes after RFCA in patients with long-standing persistent AF. A total of 161 consecutive patients with long-standing persistent AF (sustained AF duration 1 to 20 years, mean 3.4 ± 3.8) who underwent RFCA were investigated. Eplerenone was used in 55 patients and not used in the remaining 106 patients. Other conventional pharmacologic agents, including angiotensin-converting enzyme inhibitors or angiotensin type 1 receptor blockers, were used equally in the 2 groups. After 24 months of follow-up, 47% of the patients were free from AF recurrence. The rate of freedom from AF recurrence was significantly greater in the eplerenone group (60%) than in the noneplerenone group (40%) (p = 0.011). By univariate analysis, the duration of sustained AF (p
ISSN:0002-9149
1879-1913
DOI:10.1016/j.amjcard.2012.12.020